Report Shows Record Number of Cancer Drugs in Development

Publication
Article
OncologyONCOLOGY Vol 23 No 4
Volume 23
Issue 4

Responding to President Obama’s call for “a cure for cancer in our time,” the Pharmaceutical Research and Manufacturers of America recently delivered a new report on drugs in the research pipeline for cancer.

Responding to President Obama's call for "a cure for cancer in our time," the Pharmaceutical Research and Manufacturers of America recently delivered a new report on drugs in the research pipeline for cancer. The report shows that America's pharmaceutical research and biotechnology companies are testing a record 861 new cancer medicines and vaccines. The drugs listed in the report are being tested in human clinical trials or are awaiting approval by the US Food and Drug Administration.

Articles in this issue
Despite Past Disappointments the Future of Melanoma Therapy Appears Bright
Everolimus Approved for Advanced Kidney Cancer
Report Shows Record Number of Cancer Drugs in Development
Sunitinib Study in Pancreatic Cancer Stopped Early After Significant Benefit Seen
Black Cohosh (Cimicifuga racemosa)
Black Cohosh (Cimicifuga racemosa)
Clinical Trials and Radiation Oncology Technologies
Evaluating Advanced Technologies in Radiation Oncology: When and How Should Randomized Trials Be Done?
Current Status and Future Potential of Advanced Technologies in Radiation OncologyPart 2. State of the Science by Anatomic Site
Health Literacy: Improving Patient Understanding
Health Literacy, Communication, and Treatment Decision-Making in Older Cancer Patients
The Role of Adjuvant Radiation in Endometrial Cancer
The Role of Adjuvant Radiation in Endometrial Cancer
Resolving the Confusion Surrounding Adjuvant Radiation in Endometrial Cancer
Studies of Adjuvant Treatment for Endometrial Cancer
Landmark Study Shows HPV Testing Significantly Reduces Deaths from Cervical Cancer
Maintenance Rituximab Useful in Advanced Indolent Lymphoma
Recent Videos
Related Content
3 Things You Should Know About Recognizing LEMS in Patients With SCLC

3 Things You Should Know About Recognizing LEMS in Patients With SCLC

ONCOLOGY Staff
March 12th 2025
Article

In patients with small cell lung cancer, Lambert-Eaton myasthenic syndrome leads to muscle weakness and can be discovered with no-cost testing such as anti-VGCC antibody testing.

Stem Cell Transplant Approaches for Patients With Blood Cancers

Stem Cell Transplant Approaches for Patients With Blood Cancers

David T. Scadden, MD
March 13th 2019
Podcast

Dr. Scadden discusses which blood cancer patients are eligible for stem cell transplantation, as well as the latest advances in the field.

3 Things You Should Know About Treating Epithelioid Sarcoma

3 Things You Should Know About Treating Epithelioid Sarcoma

ONCOLOGY Staff
March 10th 2025
Article

Epithelioid sarcoma is individualized based on disease characteristics, it's methods of treatment vary, and systemic treatment is both targeted medication and chemotherapy.

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

Geoffrey Y. Ku, MD
March 13th 2019
Podcast

Dr. Ku discusses considerations in the treatment of esophageal cancer, current treatments, and the emerging role of immunotherapy.

Clinicians Consider Identification, Management of RCC Through the Patient’s Eyes

Clinicians Consider Identification, Management of RCC Through the Patient’s Eyes

ONCOLOGY Staff
March 8th 2025
Article

James Zoeller discussed various aspects of his cancer care after a RCC diagnosis with Hannah D. McManus, MD, and Allison Brown, BSN, RN, RN-BC.

Expanding Horizons in T-Cell Lymphoma Therapy: Focus on Personalized Treatment Strategies

Expanding Horizons in T-Cell Lymphoma Therapy: Focus on Personalized Treatment Strategies

Viviana Cortlana, PGY-4;Jade Gambill, BSc;Jenna Ghazal, BSc;Kennedy Itodo;Shreevikaa Kannan, PGY-5;Yan Leyfman, MD;Chandler H. Park, MD, FACP
March 7th 2025
Article

Several lymphoma experts discuss the current T-cell lymphoma landscape, the need for new therapies, and ongoing research in the space.